secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0000950170-25-065703
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Therapeutics reports Q1 net loss of $26.9M; cash runway into H2 2026
---------------------------------------------------------------------------

- Q1 2025 net loss $26.9M ($0.24 loss per share) vs $32.2M ($0.40 loss) in Q1 2024.
- Cash, equivalents and investments $88.2M at March 31; March public offering netted $48.8M, extending runway into H2 2026.
- TN-201 low-dose cohort showed improved NYHA class in all 3 patients and hypertrophy improvement in 2 of 3; Cohort 2 enrollment on track.
- TN-401 RIDGE-1 Phase 1b enrollment on track for H1 2025; initial data expected H2 2025.
- Restructuring with workforce reduction estimated at $1.6-$2.7M charges to extend cash runway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017025065703/0000950170-25-065703-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017025065703/tnya-20250507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-065703

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer